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Abstract: Oxidative post-translational modifications (oxPTM) of receptors, enzymes, ion channels and
transcription factors play an important role in cell signaling. oxPTMs are a key way in which oxidative
stress can influence cell behavior during diverse pathological settings such as cardiovascular diseases
(CVD), cancer, neurodegeneration and inflammatory response. In addition, changes in oxPTM are
likely to be ways in which low level reactive oxygen and nitrogen species (RONS) may contribute
to redox signaling, exerting changes in physiological responses including angiogenesis, cardiac
remodeling and embryogenesis. Among oxPTM, S-glutathionylation of reactive cysteines emerges as
an important regulator of vascular homeostasis by modulating endothelial cell (EC) responses to their
local redox environment. This review summarizes the latest findings of S-glutathionylated proteins
in major EC pathways, and the functional consequences on vascular pathophysiology. This review
highlights the diversity of molecules affected by S-glutathionylation, and the complex consequences
on EC function, thereby demonstrating an intricate dual role of RONS-induced S-glutathionylation in
maintaining vascular homeostasis and participating in various pathological processes.
Keywords: S-glutathionylation; endothelial cells; cardiovascular diseases; glutathione; oxidative
stress; reactive oxygen and nitrogen species; oxidative post-translational modifications; signal
transduction; redox
1. Introduction
Covering vascular lumen walls, endothelial cells (ECs) are a central component building the
interface between blood and underlying tissue. ECs act on multiple processes to ensure the maintenance
of systemic vascular homeostasis, including the regulation of blood pressure, haemostasis, tissue
vascularization and inflammation. Endothelial dysfunction is thus involved in a wide range of
pathologies, especially cardiovascular diseases (CVDs) such as diabetes, hypertension and peripheral
arterial disease. Importantly, the direct contact of ECs with blood circulation makes them highly
sensitive to local oxygen levels. The role of oxidative stress and high levels of reactive oxygen and
nitrogen species (RONS), resulting from ischemia/reperfusion, is now widely recognized in the
onset of CVDs [1,2]. RONS alter EC functions via inducing post-translational modifications (PTM)
on major signalling proteins involved in the main physiological processes. Those modifications
significantly modulate protein structure and activity, which highlights the potential importance of
local redox environment for driving EC functions in both physiological and pathological processes.
Among those modifications, S-glutathionylation emerges as an important modulator of EC behavior
under oxidative stress.
The harmful effects of oxPTM have been widely related to pathological processes. However,
attempts to develop antioxidant therapies to reduce oxidative damages and resolve CVDs have not met
the success expected [3]. Moreover, some antioxidant molecules reversing oxPTM, and more precisely
S-glutathionylation, recently appeared to impair key EC functions under oxidative stress such as
Antioxidants 2019, 8, 315; doi:10.3390/antiox8080315 www.mdpi.com/journal/antioxidants
Antioxidants 2019, 8, 315 2 of 25
post-ischemia revascularization [4]. More generally, antioxidants appear to contribute to pathological
processes such as lung diseases [5,6]. Further evidence for antioxidant treatment leading to adverse
effects comes from a randomized clinical trial for antioxidant use in pregnancy disorder, preeclampsia.
This trial reported a surprising secondary outcome, in which antioxidant treatment (Vitamin C and E)
caused lower birth weight with no protection against preeclampsia [7]. Taken together these findings
reveal an essential underpinning role of basal RONS levels in the maintenance of vascular homeostasis.
Our understanding of how S-glutathionylation affects EC function is developing. However, the precise
implications of this modification in physiological processes are not fully understood, and often lead to
contradictory findings. This complexity underlies a double-edge sword role of S-glutathionylation
in response to oxidative stress and suggests an example of how an ox-PTM can contribute to both
physiological and pathological processes by altering interlinked signaling pathways. It is then of
critical importance to fully understand the mechanisms by which oxPTM like S-glutathionylation can
influence EC functions to better appreciate the complex relation between oxidative stress and CVDs,
and potentially rethink our therapeutic approaches.
In this context, this review will summarize the latest insights on the role of glutathionylated
proteins in the regulation of major EC pathways, and their implications in the main physiological and
pathological processes linked with vascular homeostasis.
2. Protein S-Glutathionylation
After translation, proteins undergo various modifications including palmitoylation, phosphorylation
or hydroxylation, which alter protein function through changes in cellular location, activity or stability.
Cysteinyl residues are especially sensitive to levels of oxygen and nitrogen species (RONS), resulting in
a range of oxidative post-translational modifications (PTM) including S-nitrosylation, S-sulfenylation
and S-glutathionylation.
Under physiological RONS levels, the antioxidant molecule glutathione (GSH) can bind to specific
reactive cysteinyl residues via the creation of reversible disulfide bonds depending on the cysteine
position and redox potential. This process of S-glutathionylation can be reversed by thiol modifying
enzymes, predominantly glutaredoxin (Grx), and appears as a protective mechanism against permanent
protein damage following irreversible cysteine oxidation, summarized in Figure 1.
The different molecular mechanisms involved in S-glutathionylation PTM have been extensively
reviewed [8,9]. Beyond its protective functions, S-glutathionylation can directly modulate the structure
and activity of redox sensitive proteins by modulating their global molecular mass and charge,
or preventing other molecules to bind to their active sites [10]. Targeting a wide-range of proteins
involved in key cellular processes acting from transcriptional, structural to post-translational levels,
S-glutathionylation is now emerging as a key regulator of major signaling pathways in combination
with other posttranslational regulatory mechanisms [11,12]. In this review, we will focus on the
literature demonstrating S-glutathionylation involvement in endothelial signaling pathways and thus
its importance in cardiovascular diseases. The wide range of proteins with redox sensitive thiols
involved in EC function, and the impact of S-glutathionylation on the corresponding protein activity
are summarized in Table 1. This gives an overview of the breadth and impact that S-glutathionylation
can have on EC function.
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Table 1. Summary of S-glutathionylation activation (green) or inhibition (red) effects on major molecular players in endothelial cell (EC) function and their
physiological consequences.
Protein Name Protein Type GlutathionylatedCysteine(s) Direct Effect(s) on Protein Physiological Effect(s) in ECs Reference(s)
4.1. Epigenetics regulators
Histone H3 Nucleosomal C110 Not confirmed Regulation of gene expression viamodulating chromatin structure [13,14]
Sirtuin1 Histone deacetylase C67 C268 C623 Inhibition of enzymatic activity Apoptosis - Senescence [15–17]
4.2. Transcription factors
p65 Unknown Inhibition of nuclear translocation [18]
p50 C62
Angiogenesis & cell survival
[19]
c-jun C269
Inhibition of DNA-binding activity
Unknown [20,21]
p53 C124 C141 C182 Inhibition of DNA-binding andprotein dimerization
Angiogenesis & cell survival
(supposed) [22]
HIF-1a C520 Protein stabilization Angiogenesis & ischemicrevascularisation [23,24]
STAT3 C328 C542 Inhibition of phosphorylation andactivity
Anti-angiogenesis and reduced
inflammation [25–28]
STAT1
Transcription factor
C324 C492 Protein activation Unknown [28]
Keap1 Nrf2 inhibitor C434 Inhibition of Nrf2 binding Antioxidant and anti-inflammatoryresponse via Nrf2 signalling [29,30]
IKKb Kinase C179 Inhibition of kinase activity Angiogenesis & neovascularisation [31]
5. Kinases & phosphatases
LMW PTP Unknown Cell migration and angiogenesis [32]
PTP1B
Phosphatase
C215 Not confirmed [33,34]
Rac1
Small Rho GTPase
C81 C157
Inhibition of activity
Altered actin structure and barrier
function [35,36]
Rac2 C157 Increased GTP-binding activity Unknown [36,37]
Ras GTPase C118 Not confirmed Unknown [36,38,39]
PKA C199 [40,41]
PKB Unknown [40,42,43]
MEKK1 C1238 [40,44]
PKC
Kinase
Unknown
Inhibition of activity
Alteration of barrier function and
blood pressure regulation
(supposed)
[40,45]
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Table 1. Cont.
Protein Name Protein Type GlutathionylatedCysteine(s) Direct Effect(s) on Protein Physiological Effect(s) in ECs Reference(s)
6. RONS production
p47 phox NADPH oxidase C98 C111 C196 [46]
Complex I NADH-ubiquinoneoxidoreductase Unknown
Enhanced protein function Sustained superoxide production
Endothelial dysfunction (supposed) [47]
eNOS Oxide synthase C689 C908 Protein uncoupling
Sustained superoxide production
Impaired vasodilation and
endothelial dysfunction
[48–52]
7. Calcium-dependent channels
IP3R Ca2+ channel
Unknown (C34
C42 C65?) Protein activation [53–55]
PMCA Unknown Protein inhibition
Increased [Ca2+]i
Regulation of Ca2+ homeostasis [56]
SERCA2b Ca
2+ ATPase pump C674 Protein activation Increased Ca
2+ uptake in ER stores
Cell migration and angiogenesis
[57–62]
STIM1 Ca2+ sensor C56 Protein oligomerization
Increased [Ca]i via Orai1 activation
Mitochondrial dysfunction [63]
8. Apoptosis and autophagy
Fas Death receptor C294 Enhanced activity Cell death [64]
Caspase-3 C45 (p12)C135 (p17) [65,66]
Caspase-8
Protease
Unknown
Inhibition of proteolytic activity Cell survival
[67]
Beclin-1 Autophagy-relatedprotein Unknown Upregulation of protein activity Not confirmed [68]
9. Cell structure and dynamics
ProMMPs Metalloprotease
PRCGVPD motif
on inhibitory
domain
Activation Angiogenesis and vascularpermeability [69]
ICAM-1 Adhesion receptor Unknown Protein degradation Cell junction disassembly [70]
Actin C374 Inhibition of cell motility [71–73]
Microtubules
Cytoskeletal
Unknown
Inhibition of polymerization
Cell growth arrest and apoptosis [74,75]
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Figure 1. General mechanisms of reversible protein S-glutathionylation. Free thiols on reactive cysteinyl
residues can be modified after the formation of an intermediate thiol derivative, or more rarely undergo
direct thiol-disulfide exchange. S-glutathionylation can be reversed by the action of thiol-modifying
enzymes, e.g., glutaredoxin (Grx). Cys = cysteine, GSH = glutathione.
3. Role of Endothelium in Vascular Physiology
Endothelial cells (ECs) are a specialized tissue lining the lumen of all blood vessels. At the
interface between circulating blood and underlying tissues, ECs have multiple functions (Figure 2)
including: (a) maintenance of a selective permeability barrier between both compartments to
coordinate the passage of macromolecules, ions or signaling molecules through endothelial junctions
or intracellular clefts; (b) maintenance of hemostasis through tight spatial and temporal interplays
between pro-thrombotic, anti-coagulant, anti-platelet and fibrinolytic activities and the regulation
of blood cell-vessel wall interactions; (c) involvement in innate and adaptive immune responses
and inflammation; (d) modulation of vascular smooth muscle tone and thus blood flow distribution
and control of blood pressure; (e) formation of new blood vessels, or angiogenesis, through the
regulation of vessel wall cell proliferation and apoptosis; and (f) a contribution to the maintenance
of a quiescent, differentiated vascular smooth muscle phenotype. This broad array of EC functions
is ensured by multiple actors involved in orchestrated signalling pathways to maintain vascular
homeostasis (Figure 2). Figure 2 depicts some of the key proteins involved in EC function, which are
modification by S-glutathionylation that will be reviewed herein. Since ECs are found in all organs,
a proper interplay between these pathways is essential to a wide range of physiological functions.
In contrast, EC activation or dysfunction can lead to various pathologies. Endothelial activation is
a term used to describe reversible phenotypical changes of the endothelium, notably an increase in
adhesion molecule expression, and includes a wide spectrum of events such as variations in signaling
cascades, transcription factors, gene expression and the cytoskeleton. Endothelial dysfunction entails
pathophysiological dysregulation, which is at the extreme range of endothelial activation where it
becomes permanent or maladaptive, contributing to the development of pathological conditions.
Endothelial dysfunction is often present many years before the manifestation of clinical disease
symptoms, for example in the case of type-2 diabetes and Alzheimer’s disease.
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Figure 2. Schematic representation of the main endothelial cell functions and associated molecular
pathways which are suspectable to S-glutathionylation.
4. Transcription Regulation by S-Glutathionylation: Epigenetics Regulators and Transcription Factors
4.1. Epigenetic Regulators
The importance of epigenetics in EC function and related complex diseases is meeting a growing
interest, highlighted by the recent emergence of whole genome studies. The modification of histone
methylation state plays a key role in EC function by acting upstream of gene transcription, and its
implications in cardiovascular pathologies [76]. Importantly, epigenetics appears as an essential player
in EC progenitor function, therefore regulating vascular repair processes [77,78]. Histone modifications
are particularly important for regulating the expression of key EC genes as the endothelial nitric oxide
synthase (eNOS) and the vascular endothelial growth factor 1 (VEGFR1), therefore playing a pivotal
role in vascular homeostasis and angiogenesis (Figure 3a) [79–81]. Oxidative stress is known to alter
chromatin structure, and S-glutathionylation occurs in histones and histone-modifying enzymes [82].
However, how S-glutathionylation directly relates to epigenetic-induced onset of cardiovascular
diseases (CVD) warrants further assessment since the following factors undergo oxPTM.
4.1.1. Histone Proteins
In eukaryotes, the chromatin is packaged in individual units called nucleosomes. Histones,
the building bricks of nucleosomes, are subject to various PTM which directly impact the chromatin
structure and, as a result, gene expression [83]. Although cysteine residues have been identified
in hist e H3 [84], studies on redox regulation processes such as S-glutathionylation on histones
have been halted by challenging technical requirements. Only recently has S-glutathionylation been
identified on histone H3 in cancerous cells [13]. S-glutathionylation of histone H3 has been confirmed
and further characterized by Olaso et al., who identified a target cysteine residue on the protein [14].
Despite altering the nucleosome structure and, therefore, chromatin compaction, the exact functional
implications of S-glutathionylation on chromatin structure are not widely appreciated. While Garcia
et al. suggested that histone H3 S-glutathionylation opens chromatin structure and promotes gene
expression [14], another study claimed opposite effects [85]. These discrepancies may be due to
the difficulty in studying highly reversible oxidative modifications. Further studies are required to
elucidate the functional consequences of histone H3 S-glutathionylation on gene expression, and the
potential existence of other S-glutathionylation modifications on other reactive Cys in histone H3
previously identified [14,84].
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Figure 3. Overview of the interlinked effects of S-glutathionylation in major EC functions via the
alteration of (a) major signaling pathways in cytosol and nucleus (b) RONS formation in mitochondria
(c) calcium-dependent signaling in the endoplasmic reticulum.
4.1.2. Histone-Modifying Enzymes
The effect of S-glutathionylation on the modulation of chromatin structure can be appreciated
indirectly, vi the modification of histone-modifying enzymes. Pa ticularly, RONS are known t decr ase
histone d acetylase (HDAC) activity, notably via nitrosylat on, favoring gene transcription 86,87].
However, the role of S-glutathionylation in the regul tion of histone acetylation state and implicatio s in
EC physiology is only starting to be e ucidated with sirtuins. This family of proteins plays an important
role in the regu of endothelial cell homeos asis via deacetylation of multiple targets [88].
In d ition to its role in a giog nesis and diastolic functions [89,90], sirtuin 1 (SIRT1), also called
“longevity protein”, appears to play a protec ve role in EC response to oxidative stress by reduci g
RONS levels. While p65 gene deacetylation by SIRT1 inhibits nuclear factor kappa-light-chain-enhancer
of activated B cells (NFκB) signaling [91,92], the sam process en ances eNOS activity, therefore
promoting nitric oxide (NO) production and v sodilation while reducing RONS production [93,94].
Three cyst ines ave been identified as susceptible to thiol modific tions SIRT1 [15], and the
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presence of S-glutathionylation has been confirmed [16]. SIRT1 S-glutathionylation appears to inhibit
enzymatic activity by altering protein structure and binding to nicotinamide adenine dinucleotide
(NAD+), leading to cell senescence and apoptosis (Figure 3a) [17].
4.2. Transcription Factors
S-glutathionylation regulates various transcription factors in ECs, most of the time by inhibiting
their activity and, therefore, silencing the expression of downstream targets (Figure 3a). Interestingly,
some exceptions were reported where this modification had opposite effects, enhancing gene expression.
The redox regulation of transcription factors illustrates the complexity of S-glutathionylation acting to
switch effects in multiple signaling pathways and its potential clinical implications.
4.2.1. S-Glutathionylation-Mediated Inhibition of Transcription Factors
NFκB transcription factor complex is mostly known for its pro-inflammatory properties,
characterized in ECs by a promotion of vascular permeability and leukocyte recruitment [95]. Besides
promoting inflammation, NFκB also plays a key role in the regulation of angiogenesis and cell survival,
notably via Wnt5a signaling pathway [4,96].
S-glutathionylation regulates various components of the NFκB pathway. NFκB major subunits p50
and p65 activity are inhibited by S-glutathionylation, preventing DNA-binding or nuclear translocation
and downstream gene transcription [18,19]. S-glutathionylation was also reported in the protein kinase
IKKb, which impaired its kinase activity and, therefore, further promotes the p65/p50 sequestration
in the cytosol [31]. The consequences of S-glutathionylation-induced inhibition of NFκB have been
demonstrated in various inflammatory diseases and have been extended to ECs. Recent studies
highlighted an essential role of this process for neovascularization response. This is in accordance with
the recognized antiangiogenic properties of NFκB signaling via the production of the antiangiogenic
factor soluble Vascular growth factor receptor 1 (sVEGFR1) (Figure 3a). [42,43]. Previous studies,
however, suggested that NFκB inhibition by S-glutathionylation in mice fibroblasts promoted cell
hypoxic apoptosis [44].
As a component of the AP-1 transcription factor complex, c-Jun protein promotes cell proliferation
and angiogenesis in ECs. However, its precise roles in cell survival are still controversial. The signaling
cascade of c-Jun is known to be susceptible to redox regulation [43–100]. Displaying a particularly
high redox potential, S-glutathionylation of its Cys269 residue has been extensively reported
(Figure 3a) [20,21]. This oxPTM inhibits the DNA binding of c-jun, with the functional consequence in
ECs and may contribute to invasive breast cancer and/or pulmonary hypertension [43,100].
p53 is gatekeeper of a wide range of cellular pathways, mostly known for its antitumorigenic
properties preventing abnormal cells proliferating. However, the role of p53 in non-cancerous cells
such as ECs has recently attracted interest due to its crucial implications in angiogenesis, apoptosis
and vascular dysfunction [101]. p53 S-glutathionylation inhibition of DNA binding and protein
dimerization has been reported in cancerous cells [22], having potential implications in EC function
and vascular pathologies associated with defects in angiogenesis regulation.
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a basic redox-regulated leucine zipper protein,
is another major transcriptional factor that plays fundamental roles in EC functions including
essential anti-angiogenic activity. In response to oxidative stress, Nrf2 mediates antioxidant and
anti-inflammatory signals providing crucial cytoprotective effects in many cells types including the
endothelium(Figure 3a) [102]. The range of cytoprotective proteins induced by Nrf2 activation include
NADPH quinone oxidoreductase 1, sulfiredoxin 1, Heme oxygenase-1 and glutathione S-transferases.
In addition, Nrf2 regulates angiogenesis post ischemia [103]. A novel role of S-glutathionylation in
modulating Nrf2 activity was recently reported in various cell types, where S-glutathionylation of its
inhibitor Keap1 results in Nrf2 nuclear translocation and expression of its downstream targets [29,30].
Those findings highlight the importance of S-glutathionylation in cell response to oxidative stress.
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4.2.2. S-Glutathionylation-Mediated Activation of Transcription Factors
Hypoxia-inducible factor 1-alpha (HIF-1α) is the major regulator of oxygen homeostasis in
ECs, and promotes angiogenic signaling in response to hypoxia [104]. Alterations in the protein
activity, therefore, play a crucial role in severe pathological states associated with ischemia [105].
The role of HIF-1a S-glutathionylation was extensively studied in cancerous cells. In the hypoxic
tumor environment, this modification stabilizes the protein and, therefore, promotes tumor growth
and angiogenesis (Figure 3a) [23]. Accordingly, the promotion of S-glutathionylation of HIF-1α in
endothelial cells was found to accelerate ischemic revascularization via VEGF-A production in animal
models [24], showing important implications in the mechanism of recovery from ischemic injury.
4.2.3. Opposite Effects of S-Glutathionylation on Various Signal Transducer and Activator of
Transcription (STAT) Proteins
The JAK/STAT signaling pathway is activated in response to cytokines and growth factors and
stimulates a wide range of physiological processes including inflammation, apoptosis, differentiation,
cell migration and proliferation. In this pathway, Signal Transducer and Activator of Transcription
(STAT) family proteins are intracellular transcription factors phosphorylated by JACK, and translocated
to the nucleus to promote gene expression (Figure 3a) [106]. These include STAT1 and STAT3, activated
not only by cytokine receptors but also by Vascular Endothelial Growth Factor (VEGF) signaling in
endothelial cells. STAT pathway, therefore, plays a role in angiogenic response and cell growth [107,108].
Beyond their role in angiogenesis, STATs are highly important in promoting EC inflammatory response,
and are known to play a role in atherosclerosis progression [109,110].
S-glutathionylation of STAT3 prevents phosphorylation inhibiting DNA-binding capacities [25],
and a more recent study identified two reactive cysteine residues subject to S-glutathionylation in STAT3
structure [26]. Carbon monoxide (CO)-mediated S-glutathionylation of the reactive cysteines under
mild oxidative conditions exerts a cytoprotective mechanism, modulating pro-inflammatory signals in
ECs [27]. S-glutathionylation of STAT1 was observed in microglial cells. Interestingly, the effects of
this modification appear contrary to the ones observed with STAT3, as STAT1 phosphorylation was
not impaired by S-gluathionylation and activity was enhanced [26]. STAT3 and STAT1 have been
shown to have antagonistic effects on angiogenesis and cell proliferation in endothelial cells [111,112].
Although inducing opposite effects on the two STAT proteins, S-glutathionylation seems to exhibit
a general inhibitory role on JACK-STAT-mediated angiogenesis.
5. Redox Control of Phosphorylation by S-Glutathionylation: Phosphatases, GTPases and Kinases
Protein phosphorylation is a pivotal post-translational modification regulating cell signaling
pathways. Phosphatase and kinase enzymes regulate the phosphorylation state of major proteins
in EC signaling as receptors and downstream targets (Figure 3a). While cysteine oxidation is
generally considered as an inhibitor of phosphatase activity, the effects on kinases requires further
investigation [113,114]. The example of S-glutathionylation seems to follow this pattern and could
bring novel insights into the redox regulation of phosphorylation in key EC signaling pathways and
effects of oxidative stress in pathophysiological conditions.
5.1. Phosphatases
Protein tyrosine phosphatases (PTP) down-regulate key receptors by dephosphorylating
kinase domains.
Low-molecular-weight protein tyrosine phosphatase (LMW-PTP) family proteins inhibit growth
factors regulating cell growth and angiogenesis, but also inhibit focal adhesion kinase regulating cell
migration. LMW-PTP, characterized by the presence of two reactive cysteines located in their catalytic
domain, are widely recognized as a redox-dependent “molecular switche” in many cell types [115–117].
More specifically, S-glutathionylation was shown to inhibit LMW-PTP phosphatase activity in ECs
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and, therefore, appears essential for promoting angiogenesis and EC migration [32]. This same study
demonstrated that this modification was mediated by VEGF-dependent ONOO-, highlighting its role
in a negative feedback loop central to VEGF signaling.
PTP1B is a major regulator of EC proliferation through its binding and inactivation of the VEGFR2
receptor. Its phosphatase activity on tyrosine domains also applies to the VE-cadherin receptor,
stabilizing cell–cell adhesion and, therefore, limiting vascular permeability [118]. S-glutathionylation
inhibits PTP1B activity [33,34]. Although the functional consequences of this modification were not
studied in directly in ECs, mice lacking PTP1B display enhanced angiogenic and revascularization
capacities as well as an increased cardiac perfusion following myocardial infarction [119]. Further
studies are needed to investigate the potential implications of PTP1B inhibition by S-glutathionylation
in cardiovascular diseases related to VEGF and VE-cadherin signaling. S-glutathionylation could also
appear as a key redox switch for the regulation of other PTPs such as HCPTPA, also involved in VEGF
receptor inhibition [120].
5.2. GTPases
GTPases, hydrolyze GTP to provide the energy required for central physiological processes, play
an important role in the regulation of vascular permeability and RONS production. Defects in vascular
barrier function are a hallmark of vascular dysfunction, promoting leukocyte transmigration and chronic
inflammation, and have been associated with various severe pathologies such as diabetes [121,122] or
pulmonary disorders [123]. Enhanced RONS and S-glutathionylation levels appear to promote vascular
permeability, suggesting redox control [35,123]. However, which components are S-glutathionylated
and how this process affects vascular permeability is yet to be described in detail.
Small Rho GTPases act in a complex interplay to modulate the dynamics of the actin cytoskeleton,
a central feature for EC barrier function and migration [124,125]. GTPases are recognized as
redox-sensitive and generally inhibited by oxidative stress [38]. Among them, Ras-related C3 botulinum
toxin substrate 1 (Rac1) S-glutathionylation was recently shown to alter the enzyme function, resulting
in loss of cortical actin structure, increased stress fibers and cell–cell adherens junction disassembly [35].
On the contrary, another study evidenced the opposite effect on Rac2, on which S-glutathionylation
appeared to enhance GTP-binding activity [37]. The Ras subfamily of GTPases S-glutathionylation
was observed in ECs and smooth muscle cells (SMC). However, the biological effects on nucleotide
exchange and protein activity remain controversial [87,89,90].
Beyond the regulation of vascular barrier integrity, further understanding of Rho GTPase redox
regulation could provide important insights on EC response to oxidative stress through NADPH
oxidase and eNOS activation [36–126] and, therefore, angiogenesis and cell migration [127].
5.3. Kinases
Kinase proteins are now widely recognized as redox-regulated, and more specifically subject to
inhibition by S-glutathionylation due to the presence of a reactive cysteine residue in their catalytic
domain [40]. It is notably the case for protein kinase B (PKB), which activity was maintained by Grx in
various studies [42,43]. PKA, PKC and mitogen-activated protein kinase (MEK) are other examples of
S-glutathionylation-induced inhibition of kinase activity [45–98].
Although precise biological implications of protein kinase redox regulation have not been
extensively explored in ECs, the results showing that their enzymatic activities are importantly altered
by S-glutathionylation could have crucial impacts for EC physiology. Indeed, the role of various
kinases in key EC functions, especially the regulation of vascular barrier function and blood pressure,
is well established [128,129].
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6. S-Glutathionylation Effects on RONS Production
6.1. NADPH Oxidase Complex
In ECs, the major source of RONS is a NADPH oxidase (NOX) homologue. Upon activation
by VEGF, ET-1, Angiotensin II (AngII) or Transforming Growth Factor β (TGFβ), the production
of superoxide (O2−) and hydrogen peroxide from NOX regulates multiple redox-dependent
pathways, especially those involved in the regulation of vascular tone and angiogenesis through NO
inhibition [130–132] (Figure 3a). As a result, NOX-dependent RONS expression induces endothelial
dysfunction and various cardiovascular pathologies such as hypertension, diabetes and cardiac
failure [4,106–135]. The activation of the catalytic transmembrane unit relies on interactions between
several cytosolic proteins, including cytosolic phox subunits and Rac1 [136,137]. In addition to Rac1
S-glutathionylation mentioned previously, p47phox S-glutathionylation was reported in neutrophils
on three cysteines, in which the modification appears essential to drive sustained O2− generation [46].
Interestingly, S-glutathionylation did not alter the protein phosphorylation state of p47phox, essential
for its activation. As p47phox was identified as a key factor for RONS production in ECs stimulated by
TNF-α [138], p47phox S-glutathionylation could then appear as an upstream redox switch promoting
endothelial dysfunction through multiple target oxidation. However, further studies are needed to
confirm that a similar effect is observed in EC despite some variations in vascular NOX properties
compared to phagocytic cells [139]. A similar effect was observed on mitochondrial Complex I, another
major source of O2− in EC (Figure 3b) [47,140].
6.2. Endothelial Nitric Oxide Synthase System
eNOS is the major source of NO in ECs. This soluble gasotransmitter plays a central role in vascular
homeostasis by regulating vascular tone, angiogenesis and maintenance of barrier integrity. The effects
of RONS on eNOS activity are now generally recognized. Under oxidative stress, eNOS adopts
a NADPH oxidase function and switches from NO to O2− generation, which is a hallmark of multiple
cardiovascular pathologies including atherosclerosis [141]. The role of eNOS S-glutathionylation in
this process has recently met a growing interest. eNOS S-glutathionylation at the reductase site
alters electron transfer and, therefore, uncouples eNOS, promoting O2− over NO generation [48].
Since then, the role of S-glutathionylation has been further assessed [142] and shown in different
pathologies such as hypoxia/reoxygenation injury [49] or necrotizing enterocolitis [50]. Importantly,
eNOS S-glutathionylation is NADPH oxidase dependent [51,52], potentially contributing to NO
inhibition resulting from O2− production by NOS (Figure 3a).
7. S-Glutathionylation Effects on Ca2+ Homeostasis
Major functions of EC including angiogenesis, cell migration and growth, all depend on cytosolic
calcium ion (Ca2+) concentrations ([Ca]i), tightly regulated by calcium-dependent channels located at
the surface of the endoplasmic reticulum (ER), mitochondria and plasma membrane (Figure 3c) [143].
The effects of oxidative stress, and more precisely oxidized glutathione, on [Ca2+]i modulation have
been reported [53,144], suggesting S-glutathionylation as a potential regulator of cellular Ca2+ handling.
7.1. Calcium-Dependent IP3R & PMCA Channels
Lock et al. were the first to show that direct modification of inositol trisphosphate receptor
(IP3R) and plasma membrane Ca2+ ATPase (PMCA) by S-glutathionylation have an effect on Ca2+
oscillatory patterns and [Ca2+]i [56]. Interestingly, opposite effects were observed on each channel:
while S-glutathionylation appeared to inhibit PMCA activity, it was shown to enhance IP3R activity,
both increasing Ca2+ entry into aortic EC cytosol [56]. This latter effect was further explored in a later
study which suggested that S-glutathionylation enhanced the receptor sensitivity to cytosolic Ca2+,
leading to increased Ca2+ leaking into the cytosol [54]. Despite the identification of several cysteines
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potentially subject to S-glutathionylation in it the receptor structure, [55], whether this enhanced activity
is due to direct protein modification or S-glutathionylation of accessory components is not known.
7.2. SERCA2b Calcium Pump
The sarco/endoplasmic reticulum calcium ATPase2 (SERCA2) pump promotes Ca2+ uptake in
ER stores in ECs and SMC, directly regulating downstream processes involved in the maintenance
of vascular homeostasis [145]. The importance of SERCA2 S-glutathionylation was first identified in
SMC, in which NO-induced S-glutathionylation on one reactive cysteine enhanced protein uptake
activity and muscle relaxation. S-glutathionylation of SERCA2 was well characterized, yet it is not
clear how it leads to increased uptake by the pump [146].
This finding brought novel insights on the redox regulation of EC functions in response to hypoxia.
Recent studies pointed out the essential role of SERCA S-glutathionylation in VEGF-induced EC
migration via NOX signaling [57,147]. Thompson et al. further confirmed the physiological implications
by showing that reversible SERCA2 S-glutathionylation was required for hypoxia-induced angiogenic
responses in mouse models [58]. Another study proposed a multiplayer model where SERCA2
S-glutathionylation in EC and macrophages is essential for their interplay leading to angiogenic
response [59]. Altogether, those results provide novel insights in the importance of redox-regulated
Ca2+ store maintenance in VEGF-induced angiogenic response in EC.
The multiple effects of SERCA2 S-glutathionylation in SMC, EC and macrophages emphasize its
importance in CVDs. This reversible modification appears as a protective mechanism against permanent
SERCA oxidation, linked to severe conditions including atherosclerosis, cardiac dysfunctions, diabetes
and impaired ischemic revascularization [90,132,134–136].
7.3. STIM1 Molecule and ORAI1 Channel
Stromal interaction molecule 1 (STIM1) senses Ca2+ contents of ER stores and replenishes them
by activating calcium release-activated calcium channel protein 1 (Orai1) promoting Ca2+ entry into
the cell [148]. S-glutathionylation was shown on one highly conserved reactive cysteine of STIM1,
leading to protein oligomerization in fibroblasts. This process triggered a constitutive activation of
Orai1, therefore, increasing global Ca2+ entry into intracellular stores. This sustained mitochondrial
Ca2+ overload alters its function, resulting in cell death [63]. Highly expressed in EC, STIM1 is key
to the maintenance of cell apoptosis and barrier integrity via both Ca2+ dependent and independent
pathways and is, therefore, an important player in inflammation [130,132,133].
8. S-Glutathionylation Effects on Cell Death and Autophagy
8.1. Apoptotic Signalling
EC apoptosis is a central process of vascular homeostasis, as it maintains vasculature turnover
and tightly regulates network formation during angiogenesis [149]. In addition to causing defects in
vessel network formation, the dysregulation of apoptosis contributes to pathological conditions such
as atherosclerosis via factors released by extracellular vesicles throughout the process [150]. Oxidative
stress is regarded as a general mediator of EC apoptosis [151,152].
One aspect of the apoptotic process in EC involves the activation of the death receptor Fas [153]
also involved in the maintenance of vascular integrity [154,155]. S-glutathionylation is suggested to
upregulate the receptor activity and subsequent apoptotic signaling (Figure 3a) [64].
The apoptotic response is mediated by a cascade activation of the proteolytic enzymes
cysteine-aspartic proteases (Caspases) downstream death receptors [153]. Caspase active sites,
composed of cysteines, by definition are interesting targets for deciphering the role of redox-dependent
thiol modifications such as S-glutathionylation in EC death receptor signaling pathway. The importance
of thiol modifications in Caspases were first highlighted when a disulfide bond formation on Caspase-1
thiol inhibited its activity [156]. Pan et al. demonstrated that S-glutathionylation of Caspase-3 stabilizes
Antioxidants 2019, 8, 315 13 of 25
the enzyme, inhibiting its cleavage required for activation, therefore, inhibiting apoptosis in EC [65].
Caspase-3 S-glutathionylation was further characterized in various cell types, in a study revealing
two cysteines undergoing S-glutathionylation. While one is located in the enzymatic site, it remains
to be discovered how the second one affects enzymatic activity [66]. Similarly, S-glutathionylation
of caspase-8 in mice models seems to inhibit apoptosis, suggesting a protective mechanism against
pathologies related to cell toxicity [67].
8.2. Autophagy
Growing evidence points out a protective role of EC autophagy in various physiological
processes following oxidative stress and RONS production [157,158], as in ischemia/reperfusion
injury [159], notably by promoting NO production [160]. Apoptosis and autophagy pathways are
interlinked, and S-glutathionylation is likely to promote EC autophagy by upregulating the activity
of autophagy-related protein Beclin-1 [68]. The altered function of Beclin-1, a major mediator of
this process, was found to participate in various pathological processes such as atherosclerosis
or hypertension promoting EC dysfunctions [161,162], pointing out the potential implications of
S-glutathionylation in CVDs through autophagy regulation.
9. Redox Regulation of Cell Structure and Dynamics by S-Glutathionylation
9.1. Metalloproteases
Metalloprotease (MMP) enzymes are implicitly involved in angiogenesis by degrading endothelial
cell matrix (ECM) components, permitting the endothelial cells to migrate within tissues. MMPs also
contribute to angiogenesis releasing proangiogenic stimuli to further promote EC migration
(Figure 3a) [163]. In addition to cancer, the dysregulation of MMP activity contributes to inflammation,
and multiple cardiovascular conditions especially cardiac hypertrophy and atherosclerosis [164,165].
While previous studies pointed out the mechanisms of MMP redox regulation through the modulation
of upstream mitogen-activated protein kinase (MAPK) pathway [166,167], others identified direct
redox-dependent modifications of the MMP system. MMP activity is tightly regulated and activated in
situ by cleavage of a pro-MMP form by tissue inhibitors of metalloproteinases (TIMPs). Promising
results showed that S-glutathionylation of pro-MMP inhibitory domain could trigger the passage from
latency to activated state, therefore, enhancing angiogenesis and vascular permeability (Figure 3a) in
animal models [69,168].
9.2. Adhesion Proteins
Integrins are the major points of contact between ECs and their extracellular microenvironment,
driving cell migration, proliferation and regulating vessel permeability. In addition to promoting cell
adhesion and migration within the ECM, integrins act as receptors to trigger specific proangiogenic
signaling pathways (Figure 3a) [169]. In leukocytes, thiol-based redox regulation of integrins modulate
their structure and activity [170]. More precisely, S-glutathionylation of integrinα4 enhances the binding
of neutrophils to ECs [171,172]. Despite Integrins wide range of biological functions, the physiological
effects of EC integrins S-glutathionylation remain elusive. However, this is likely to contribute to
endothelial activation, therefore, modulating the inflammatory response.
Vascular cell adhesion protein 1 and Intercellular Adhesion Molecule 1 (VCAM-1 and ICAM-1)
are mainly expressed in ECs in response to pro-inflammatory cytokines and RONS. Adhesion proteins
play a pivotal role in EC activation and binding to leukocytes, mediating leukocyte transmigration
during inflammation and are, therefore, involved in inflammatory diseases such as rheumatoid
arthritis [173,174]. Growing evidence also suggests a role of VCAM-1 in angiogenesis via VEGF
activation, with subsequent implications in cancer progression [175]. A recent study suggested that
Tumor necrosis factor α (TNF-α) induced ICAM-1 S-glutathionylation, altering protein folding and
promoting its degradation [70]. The multiple cystine residues present on ICAM-1 make it particularly
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subject to oxidation processes, and a better understanding of redox effects on protein function could
provide novel insights on the mechanisms involved in inflammatory diseases and cancer.
9.3. Cytoskeletal Proteins
Cytoskeletal dynamics, a key feature driving vascular angiogenesis and barrier function,
are governed by polymerization and depolymerization of the two main component units, actin and
tubulin. Both proteins are highly redox-sensitive and S-glutathionylation is now recognized to
have a major impact on the regulation of polymerization-depolymerization cycles in various cell
types [71,136,176]. Polymerization-depolymerization cycles have been better characterized in actin,
on which S-glutathionylation modification on one reactive cysteine residue inhibits polymerization
and, therefore, plays a key role in the regulation of cytoskeletal dynamics driving cell motility
(Figure 3a) [71–73]. Similarly, glutathionylated microtubules appear depolymerized, promoting cell
growth arrest [74,75]. Phenotypical effects were not investigated in ECs specifically. However,
S-glutathionylation-induced changes in cytoskeletal reorganization could emerge as an important
feature altering cell motility under oxidative stress.
10. Conclusions
S-glutathionylation has emerged as a novel redox switch altering the functions of EC through
the modulation of key signaling pathways. Its importance and complexity in EC homeostasis and
cardiovascular physiopathology is highlighted by recent insights on how S-glutathionylated protein
functions are altered in interlinked molecular pathways at multiple levels (Figure 3).
It is now apparent that S-glutathionylation can coordinate gene transcription by modulating
epigenetics and transcription factors. Studies investigating the impact of S-glutathionylation in
epigenetics are still at their early stage, and further work is required to fully understand how
it alters gene expression. However, current insights demonstrate that both histone proteins and
histone-modifying enzymes are prone to S-glutathionylation, altering chromatin structure and gene
expression. Given the number of various genes regulated by those processes, novel insights on the
links between oxidative stress and epigenetics would allow a better understanding of EC signaling in
response to RONS, and highlight novel factors involved in complex diseases for which genetic factors
alone are not sufficient to explain. The effect of S-glutathionylation on transcription factors suggest
differential effects on their activity depending on the protein targeted. Accordingly, it is difficult to
define a general effect of this modification on EC physiology. However, the redox regulation of VEGF
signaling appears central to the activation of downstream transcription pathways and the alteration of
resulting EC functions.
S-glutathionylation exhibits a general inhibitory effect on enzymes by altering the structure of
their catalytic site and impairing their activity. This has important repercussions when applied to
phosphatases, GTPases and kinases, which are key signal transducers in ECs. The multiplicity of
pathways regulated by enzymatic activity underlines the crucial importance of understanding the
redox mechanisms dictating their behavior to better understand EC responses to oxidative stress.
As upstream mediators of S-glutathionylation, RONS themselves are subject to redox regulation.
The two main RONS sources in EC, NOX and eNOS, are under tight redox control. The different
effects of S-glutathionylation on RONS-producing systems have a general tendency to promote RONS
production. This suggests a retroactive system, where RONS sustain their own production, which could
importantly participate in oxidative stress-mediated EC dysfunction.
In respect to calcium signaling, S-glutathionylation tends to favor ion entry into the cell cytosol
through reversible alteration of various player functions, except for the SERCA channel. Those results
confirm that this modification plays a central role in Ca2+ homeostasis in EC, and that a tight regulation
of RONS levels is required to ensure physiological Ca2+ levels in cellular stores allowing proper
EC functions.
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The opposing effects of S-glutathionylation on different apoptotic factors may explain the complex
and diverse effect of oxidative stress on EC apoptosis.
The role of S-glutathionylation in EC autophagy is less studied, and we expect future work will
target this pathway.
Beyond signaling molecules, the influence of S-glutathionylation on cell structure components is
another example of the duality of S-glutathionylation effects. While this modification tends to lower cell
growth and motility by inhibiting cytoskeleton polymerization as well as surface adhesion molecules,
the positive effects observed on metalloprotease proteins favor cell migration within extracellular
tissues. S-glutathionylation induced degradation of adhesion molecules might also play an important
role in the regulation of leukocyte transmigration and inflammation.
All modifications depicted in this review are integrated into a diagram to reflect the complexity of
S-glutathionylation redox switch in the modulation of EC signaling pathways (Figure 3). Altogether,
these findings highlight the wide range of proteins targeted for S-glutathionylation and the diversity
of EC functions involved. This process is now recognized as a novel signaling “switch” among other
more characterized PTM such as phosphorylation.
However, the difficulty lies in finding a consistent effect of S-glutathionylation and appreciating
the complex mechanism of RONS/antioxidant balance during physiology and pathophysiology.
The importance of basal redox signaling in normal physiology could provide a better understanding
of why antioxidant therapies failed to meet expectations. Greater appreciation of redox signaling
in physiology is of upmost importance since antioxidant treatments in clinical trials have caused
unexpected adverse effects. Studies on S-glutathionylation are still at their relatively early stage
compared to other PTMs. Another aspect which requires further investigation to appreciate the
implications in cardiovascular pathophysiology is how S-glutathionylation interrelates with other
oxPTM. A better understanding of the S-glutathionylation process in EC could illuminate the
complicated relations linking oxidative stress/redox signaling with CVDs and may also be relevant for
other pathologies such as cancer and inflammatory diseases.
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[Ca2+]i cytosolic calcium ion concentrations
AngII angiotensin II
Ca2+ calcium ion
CO carbon oxide
CVD cardiovascular diseases
Cys cysteine
EC endothelial cell
ECM extracellular matrix
eNOS endothelial nitric oxide synthase
ER endoplasmic reticulum
Grx glutaredoxin
GSH glutathione
HDAC histone deacetylase
HIF-1α hypoxia-inducible factor 1α
ICAM-1 intercellular adhesion molecule 1
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LMW-PTP Low-molecular-weight protein tyrosin phosphatase
MAPK mitogen-activated protein kinase
MEK mitogen-activated protein kinase kinase
MMP matrix metalloproteinases
NAD+ nicotinamide adenine dinucleotide
NFκB nuclear factor-kappa B
NO nitric oxide
NOX NADPH oxidase
Nrf2 nuclear factor erythroid 2-related factor 2
O2 superoxide
oxPTM oxidative post-translational modifications
PKB protein kinase B
PTM post-translational modifications
PTP protein tyrosine phosphatase
Rac1 ras-related C3 botulinum toxin substrate 1
RONS reactive oxygen and nitrogen species
Sirt-1 sirtuin 1
STAT signal transducer and activator of transcription
TGF-β transforming growth factor beta
TIMPs tissue inhibitors of metalloproteinases
TNF-α tumor necrosis factor alpha
VCAM-1 vascular cell adhesion protein 1
VEGF vascular endothelial growth factor
VEGFR1 vascular endothelial growth factor receptor 1
References
1. Cervantes Gracia, K.; Llanas-Cornejo, D.; Husi, H. CVD and Oxidative Stress. J. Clin. Med. 2017, 6, 22.
[CrossRef] [PubMed]
2. Panth, N.; Paudel, K.R.; Parajuli, K. Reactive Oxygen Species: A Key Hallmark of Cardiovascular Disease.
Adv. Med. 2016, 2016, 9152732. [CrossRef] [PubMed]
3. Sorriento, D.; De Luca, N.; Trimarco, B.; Iaccarino, G. The Antioxidant Therapy: New Insights in the
Treatment of Hypertension. Front. Physiol. 2018, 9, 258. [CrossRef] [PubMed]
4. Murdoch, C.E.; Shuler, M.; Haeussler, D.J.F.; Kikuchi, R.; Bearelly, P.; Han, J.; Watanabe, Y.; Fuster, J.J.;
Walsh, K.; Ho, Y.-S.; et al. Glutaredoxin-1 Up-regulation Induces Soluble Vascular Endothelial Growth
Factor Receptor 1, Attenuating Post-ischemia Limb Revascularization. J. Boil. Chem. 2014, 289, 8633–8644.
[CrossRef] [PubMed]
5. Nolin, J.D. Redox Control of Allergic Airway Disease: Impact of Glutaredoxin-1 on Epithelial Driven
Inflammation and Allergen-Induced Airway Remodeling. Bachelor’s Thesis, The University of Vermon,
Burlington, VT, USA, 2015.
6. Kuipers, I.; Louis, R.; Manise, M.; Dentener, M.A.; Irvin, C.G.; Janssen-Heininger, Y.M.; Brightling, C.E.;
Wouters, E.F.; Reynaert, N.L. Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum
of asthmatics. Eur. Respir. J. 2013, 41, 469–472. [CrossRef] [PubMed]
7. Poston, L.; Briley, A.; Seed, P.; Kelly, F.; Shennan, A.; Seed, P. Vitamin C and vitamin E in pregnant women
at risk for pre-eclampsia (VIP trial): Randomised placebo-controlled trial. Lancet 2006, 367, 1145–1154.
[CrossRef]
8. Mieyal, J.J.; Gallogly, M.M.; Qanungo, S.; Sabens, E.A.; Shelton, M.D. Molecular Mechanisms and Clinical
Implications of Reversible Protein S-Glutathionylation. Antioxid. Redox Signal. 2008, 10, 1941–1988. [CrossRef]
[PubMed]
9. Xiong, Y.; Uys, J.D.; Tew, K.D.; Townsend, D.M. S-Glutathionylation: From Molecular Mechanisms to Health
Outcomes. Antioxid. Redox Signal. 2011, 15, 233–270. [CrossRef]
10. Cooper, A.J.L.; Pinto, J.T.; Callery, P.S. Reversible and irreversible protein glutathionylation: Biological and
clinical aspects. Expert Opin. Drug Metab. Toxicol. 2011, 7, 891–910. [CrossRef]
Antioxidants 2019, 8, 315 17 of 25
11. Dominko, K.; Đikic´, D. Glutathionylation: A regulatory role of glutathione in physiological processes.
Arch. Ind. Hyg. Toxicol. 2018, 69, 1–24. [CrossRef]
12. Grek, C.L.; Zhang, J.; Manevich, Y.; Townsend, D.M.; Tew, K.D. Causes and Consequences of Cysteine
S-Glutathionylation. J. Boil. Chem. 2013, 288, 26497–26504. [CrossRef] [PubMed]
13. De Luca, A.; Moroni, N.; Serafino, A.; Primavera, A.; Pastore, A.; Pedersen, J.Z.; Petruzzelli, R.; Farrace, M.G.;
Pierimarchi, P.; Pierimarchi, G.; et al. Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide
causes histone glutathionylation and reversal of drug resistance. Biochem. J. 2011, 440, 175–183. [CrossRef]
[PubMed]
14. García-Giménez, J.L.; Olaso, G.; Hake, S.B.; Bönisch, C.; Wiedemann, S.M.; Markovic, J.; Dasi, F.; Gimeno, A.;
Perez-Quilis, C.; Palacios, Ò.; et al. Histone H3 Glutathionylation in Proliferating Mammalian Cells
Destabilizes Nucleosomal Structure. Antioxid. Redox Signal. 2013, 19, 1305–1320. [CrossRef]
15. Autiero, I.; Costantini, S.; Colonna, G. Human Sirt-1: Molecular Modeling and Structure-Function
Relationships of an Unordered Protein. PLoS ONE 2009, 4, 1–12. [CrossRef] [PubMed]
16. Zee, R.S.; Yoo, C.B.; Pimentel, D.R.; Perlman, D.H.; Burgoyne, J.R.; Hou, X.; McComb, M.E.; Costello, C.E.;
Cohen, R.A.; Bachschmid, M.M. Redox Regulation of Sirtuin-1 by S-Glutathiolation. Antioxid. Redox Signal.
2010, 13, 1023–1032. [CrossRef] [PubMed]
17. Shao, D.; Fry, J.L.; Han, J.; Hou, X.; Pimentel, D.R.; Matsui, R.; Cohen, R.A.; Bachschmid, M.M. A
Redox-resistant Sirtuin-1 Mutant Protects against Hepatic Metabolic and Oxidant Stress. J. Boil. Chem. 2014,
289, 7293–7306. [CrossRef]
18. Liao, B.-C.; Hsieh, C.-W.; Lin, Y.-C.; Wung, B.-S. The Glutaredoxin/Glutathione System Modulates NF-κB Activity
by Glutathionylation of p65 in Cinnamaldehyde-Treated Endothelial Cells. Toxicol. Sci. 2010, 116, 151–163.
[CrossRef]
19. Pineda-Molina, E.; Klatt, P.; Vázquez, J.; Marina, A.; De Lacoba, M.G.; Pérez-Sala, D.; Lamas, S.
Glutathionylation of the p50 Subunit of NF-κB: A Mechanism for Redox-Induced Inhibition of DNA
Binding. Biochemistry 2001, 40, 14134–14142. [CrossRef]
20. Klatt, P.; Molina, E.P.; De Lacoba, M.G.; Padilla, C.A.; Martínez-Galisteo, E.; Bárcena, J.A.; Lamas, S. Redox
regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J. 1999, 13, 1481–1490. [CrossRef]
21. Klatt, P.; Molina, E.P.; Lamas, S. Nitric Oxide Inhibits c-Jun DNA Binding by Specifically
TargetedS-Glutathionylation. J. Boil. Chem. 1999, 274, 15857–15864. [CrossRef]
22. Velu, C.S.; Niture, S.K.; Doneanu, C.E.; Pattabiraman, N.; Srivenugopal, K.S. Human p53 is Inhibited by
Glutathionylation of Cysteines Present in the Proximal DNA-Binding Domain During Oxidative Stress.
Biochemistry 2007, 46, 7765–7780. [CrossRef] [PubMed]
23. Jeon, D.; Park, H.J.; Kim, H.S. Protein S-glutathionylation induced by hypoxia increases hypoxia-inducible
factor-1α in human colon cancer cells. Biochem. Biophys. Res. Commun. 2018, 495, 212–216. [CrossRef]
[PubMed]
24. Watanabe, Y.; Murdoch, C.E.; Sano, S.; Ido, Y.; Bachschmid, M.M.; Cohen, R.A.; Matsui, R. Glutathione adducts
induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1α and improve limb revascularization.
Proc. Natl. Acad. Sci. USA 2016, 113, 6011–6016. [CrossRef] [PubMed]
25. Xie, Y.; Kole, S.; Precht, P.; Pazin, M.J.; Bernier, M. S-Glutathionylation impairs signal transducer and activator
of transcription 3 activation and signaling. Endocrinology 2009, 150, 1122–1131. [CrossRef] [PubMed]
26. Butturini, E.; Darra, E.; Chiavegato, G.; Cellini, B.; Cozzolino, F.; Pucci, P.; Dell’Orco, D.; Monti, M.;
Mariotto, S. S-Glutathionylation at Cys328 and Cys542 Impairs STAT3 Phosphorylation. ACS Chem. Boil.
2014, 9, 1885–1893. [CrossRef] [PubMed]
27. Yang, Y.-C.; Huang, Y.-T.; Hsieh, C.-W.; Yang, P.-M.; Wung, B.-S. Carbon Monoxide Induces Heme Oxygenase-1
to Modulate STAT3 Activation in Endothelial Cells via S-Glutathionylation. PLoS ONE 2014, 9, e100677.
[CrossRef] [PubMed]
28. Butturini, E.; Cozzolino, F.; Boriero, D.; Carcereri de Prati, A.; Monti, M.; Rossin, M.; Canetti, D.; Cellini, B.;
Pucci, P.; Mariotto, S. S-glutathionylation exerts opposing roles in the regulation of STAT1 and STAT3
signaling in reactive microglia. Free Radic Biol. Med. 2018, 590, 191–201.
29. Carvalho, A.N.; Marques, C.; Guedes, R.C.; Castro-Caldas, M.; Rodrigues, E.; Van Horssen, J.; Gama, M.J.;
Castro-Caldas, M.; Horssen, J. S-Glutathionylation of Keap1: A new role for glutathioneS-transferase pi in
neuronal protection. FEBS Lett. 2016, 590, 1455–1466. [CrossRef]
Antioxidants 2019, 8, 315 18 of 25
30. Wang, L.; Qu, G.; Gao, Y.; Su, L.; Ye, Q.; Jiang, F.; Zhao, B.; Miao, J. A small molecule targeting glutathione
activates Nrf2 and inhibits cancer cell growth through promoting Keap-1 S-glutathionylation and inducing
apoptosis. RSC Adv. 2018, 8, 792–804. [CrossRef]
31. Reynaert, N.L.; van der Vliet, A.; Guala, A.S.; McGovern, T.; Hristova, M.; Pantano, C.; Heintz, N.H.; Heim, J.;
Ho, Y.-S.; Matthews, D.E.; et al. Dynamic redox control of NF- kappaB through glutaredoxin-regulated
S-glutathionylation of inhibitory B kinase beta. Proc. Natl. Acad. Sci. USA 2006, 103, 13086–13091. [CrossRef]
32. Abdelsaid, M.A.; El-Remessy, A.B. S-glutathionylation of LMW-PTP regulates VEGF-mediated FAK activation
and endothelial cell migration. J. Cell Sci. 2012, 125, 4751–4760. [CrossRef] [PubMed]
33. Barrett, W.C.; DeGnore, J.P.; Keng, Y.-F.; Zhang, Z.-Y.; Yim, M.B.; Chock, P.B. Roles of Superoxide Radical
Anion in Signal Transduction Mediated by Reversible Regulation of Protein-tyrosine Phosphatase 1B. J. Boil.
Chem. 1999, 274, 34543–34546. [CrossRef] [PubMed]
34. Barrett, W.C.; DeGnore, J.P.; König, S.; Fales, H.M.; Keng, Y.-F.; Zhang, Z.-Y.; Yim, M.B.; Chock, P.B. Regulation
of PTP1B via Glutathionylation of the Active Site Cysteine 215. Biochemistry 1999, 38, 6699–6705. [CrossRef]
[PubMed]
35. Han, J.; Weisbrod, R.M.; Shao, D.; Watanabe, Y.; Yin, X.; Bachschmid, M.M.; Seta, F.; Janssen-Heininger, Y.M.;
Matsui, R.; Zang, M.; et al. The redox mechanism for vascular barrier dysfunction associated with metabolic
disorders: Glutathionylation of Rac1 in endothelial cells. Redox Boil. 2016, 9, 306–319. [CrossRef] [PubMed]
36. Hobbs, G.A.; Zhou, B.; Cox, A.D.; Campbell, S.L. Rho GTPases, oxidation, and cell redox control. SmallGTPases
2014, 5, e28579. [CrossRef] [PubMed]
37. Kil, I.S.; Shin, S.W.; Park, J.-W. S-glutathionylation regulates GTP-binding of Rac2. Biochem. Biophys. Res. Commun.
2012, 425, 892–896. [CrossRef] [PubMed]
38. Mitchell, L.; Hobbs, G.A.; Aghajanian, A.; Campbell, S.L. Redox Regulation of Ras and Rho GTPases:
Mechanism and Function. Antioxid. Redox Signal. 2013, 18, 250–258. [CrossRef] [PubMed]
39. Clavreul, N.; Pimental, D.R.; Adachi, T.; Ido, Y.; Schöneich, C.; Cohen, R.A. S-glutathiolation by peroxynitrite
of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. FASEB J.
2006, 20, 518–520. [CrossRef] [PubMed]
40. Anselmo, A.N.; Cobb, M.H. Protein kinase function and glutathionylation. Biochem. J. 2004, 381, e1. [CrossRef]
[PubMed]
41. Humphries, K.M.; Juliano, C.; Taylor, S.S. Regulation of cAMP-dependent Protein Kinase Activity by
Glutathionylation. J. Boil. Chem. 2002, 277, 43505–43511. [CrossRef]
42. Wang, J.; Pan, S.; Berk, B.C. Glutaredoxin Mediates Akt and eNOS Activation by Flow in a Glutathione
Reductase-Dependent Manner. Arter. Thromb. Vasc. Boil. 2007, 27, 1283–1288. [CrossRef] [PubMed]
43. Liu, X.; Jann, J.; Xavier, C.; Wu, H. Glutaredoxin 1 (Grx1) Protects Human Retinal Pigment Epithelial Cells
from Oxidative Damage by Preventing AKT Glutathionylation. Investig. Opthalmol. Vis. Sci. 2015, 56, 2821.
[CrossRef] [PubMed]
44. Cross, J.V.; Templeton, D.J. Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the
ATP-binding domain. Biochem. J. 2004, 381, 675–683. [CrossRef] [PubMed]
45. Ward, N.E.; Stewart, J.R.; Ioannides, C.G.; O’Brian, C.A. Oxidant-InducedS-Glutathiolation Inactivates Protein
Kinase C-α (PKC-α): A Potential Mechanism of PKC Isozyme Regulation. Biochemistry 2000, 39, 10319–10329.
[CrossRef] [PubMed]
46. Nagarkoti, S.; Dubey, M.; Awasthi, D.; Kumar, V.; Chandra, T.; Kumar, S.; Dikshit, M. S-Glutathionylation
of p47phox sustains superoxide generation in activated neutrophils. Biochim. Biophys. Acta (BBA)—Mol.
Cell Res. 2018, 1865, 444–454. [CrossRef] [PubMed]
47. Taylor, E.R.; Hurrell, F.; Murphy, M.P.; Shannon, R.J.; Lin, T.-K.; Hirst, J. Reversible Glutathionylation of
Complex I Increases Mitochondrial Superoxide Formation. J. Boil. Chem. 2003, 278, 19603–19610. [CrossRef]
[PubMed]
48. Chen, C.A.; Wang, T.Y.; Varadharaj, S.; Reyes, L.A.; Hemann, C.; Hassan Talukder, M.A.; Chen, Y.R.;
Druhan, L.J.; Zweier, J.L. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function.
Nature 2010, 468, 1115–1118. [CrossRef] [PubMed]
49. De Pascali, F.; Hemann, C.; Samons, K.; Chen, C.-A.; Zweier, J.L. Hypoxia and Reoxygenation Induce
Endothelial Nitric Oxide Synthase Uncoupling in Endothelial Cells through Tetrahydrobiopterin Depletion
and S-Glutathionylation. Biochemistry 2014, 53, 3679–3688. [CrossRef]
Antioxidants 2019, 8, 315 19 of 25
50. Shang, Q.; Bao, L.; Guo, H.; Hao, F.; Luo, Q.; Chen, J.; Guo, C. Contribution of glutaredoxin-1 to
S-glutathionylation of endothelial nitric oxide synthase for mesenteric nitric oxide generation in experimental
necrotizing enterocolitis. Transl. Res. 2017, 188, 92–105. [CrossRef]
51. Galougahi, K.K.; Liu, C.; Gentile, C.; Kok, C.; Nunez, A.; Garcia, A.; Fry, N.A.S.; Davies, M.J.; Hawkins, C.L.;
Rasmussen, H.H.; et al. Glutathionylation Mediates Angiotensin II–Induced eNOS Uncoupling, Amplifying
NADPH Oxidase—Dependent Endothelial Dysfunction. J. Am. Heart Assoc. 2014, 3, 1–11. [CrossRef]
52. Wu, F.; Szczepaniak, W.S.; Shiva, S.; Liu, H.; Wang, Y.; Wang, L.; Wang, Y.; Kelley, E.E.; Chen, A.F.;
Gladwin, M.T.; et al. Nox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide
production and endothelial barrier dysfunction in acute lung injury. Am. J. Physiol. Cell. Mol. Physiol. 2014,
307, L987–L997. [CrossRef] [PubMed]
53. Henschke, P.N.; Elliott, S.J. Oxidized glutathione decreases luminal Ca2+ content of the endothelial cell
ins(1,4,5) P3 -sensitive Ca2+ store. Biochem. J. 2015, 312, 485–489. [CrossRef] [PubMed]
54. Lock, J.T.; Sinkins, W.G.; Schilling, W.P. Protein S-glutathionylation enhances Ca2+-induced Ca2+ release via
the IP3 receptor in cultured aortic endothelial cells. J. Physiol. 2012, 590, 3431–3447. [CrossRef] [PubMed]
55. Kang, S.; Kang, J.; Kwon, H.; Frueh, D.; Yoo, S.H.; Wagner, G.; Park, S. Effects of Redox Potential and Ca2+ on
the Inositol 1,4,5-Trisphosphate Receptor L3-1 Loop Region. J. Biol. Chem. 2008, 283, 25567–25575. [CrossRef]
[PubMed]
56. Lock, J.T.; Sinkins, W.G.; Schilling, W.P. Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured
aortic endothelial cells. AJP Heart Circ. Physiol. 2011, 300, H493–H506. [CrossRef] [PubMed]
57. Evangelista, A.M.; Thompson, M.D.; Bolotina, V.M.; Tong, X.; Cohen, R.A. Nox4- and Nox2-dependent
oxidant production is required for VEGF-induced SERCA cysteine-674 S-glutathiolation and endothelial cell
migration. Free Radic. Boil. Med. 2012, 53, 2327–2334. [CrossRef] [PubMed]
58. Thompson, M.D.; Mei, Y.; Weisbrod, R.M.; Silver, M.; Shukla, P.C.; Bolotina, V.M.; Cohen, R.A.; Tong, X.
Glutathione adducts on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase Cys-674 regulate endothelial cell
calcium stores and angiogenic function as well as promote ischemic blood flow recovery. J. Biol. Chem. 2014,
289, 19907–19916. [CrossRef]
59. Mei, Y.; Thompson, M.D.; Shiraishi, Y.; Cohen, R.A.; Tong, X. Sarcoplasmic/endoplasmic reticulum Ca2+
ATPase C674 promotes ischemia- and hypoxia-induced angiogenesis via coordinated endothelial cell and
macrophage function. J. Mol. Cell. Cardiol. 2014, 76, 275–282. [CrossRef]
60. Sharov, V.S.; Dremina, E.S.; Galeva, N.A.; Williams, T.D.; Schöneich, C. Quantitative mapping of
oxidation-sensitive cysteine residues in SERCA in vivo and in vitro by HPLC–electrospray-tandem MS:
Selective protein oxidation during biological aging. Biochem. J. 2006, 394, 605–615. [CrossRef]
61. Tong, X.Y.; Hou, X.; Jourd’Heuil, D.; Weisbrod, R.M.; Cohen, R.A. Upregulation of Nox4 by TGFβ1 Oxidizes
SERCA and Inhibits NO in Arterial Smooth Muscle of the Prediabetic Zucker Rat. Circ. Res. 2010, 107, 975–983.
[CrossRef]
62. Qin, F.; Siwik, D.A.; Pimentel, D.R.; Morgan, R.J.; Biolo, A.; Tu, V.H.; Kang, Y.J.; Cohen, R.A.; Colucci, W.S.
Cytosolic H2O2 mediates hypertrophy, apoptosis, and decreased SERCA activity in mice with chronic
hemodynamic overload. Am. J. Physiol. Circ. Physiol. 2014, 306, H1453–H1463. [CrossRef] [PubMed]
63. Hawkins, B.J.; Irrinki, K.M.; Mallilankaraman, K.; Lien, Y.-C.; Wang, Y.; Bhanumathy, C.D.; Subbiah, R.;
Ritchie, M.F.; Soboloff, J.; Baba, Y.; et al. S-glutathionylation activates STIM1 and alters mitochondrial
homeostasis. J. Cell Boil. 2010, 190, 391–405. [CrossRef] [PubMed]
64. Anathy, V.; Aesif, S.W.; Guala, A.S.; Havermans, M.; Reynaert, N.L.; Ho, Y.-S.; Budd, R.C.;
Janssen-Heininger, Y.M. Redox amplification of apoptosis by caspase-dependent cleavage of glutaredoxin 1
and S-glutathionylation of Fas. J. Cell Boil. 2009, 184, 241–252. [CrossRef] [PubMed]
65. Pan, S.; Berk, B.C. Glutathiolation Regulates Tumor Necrosis Factor-α–Induced Caspase-3 Cleavage and
Apoptosis. Circ. Res. 2006, 100, 213–219. [CrossRef] [PubMed]
66. Huang, Z.; Pinto, J.T.; Deng, H.; Richie, J.P. Inhibition of Caspase-3 Activity and Activation by Protein
Glutathionylation. Biochem. Pharmacol. 2008, 75, 2234–2244. [CrossRef] [PubMed]
67. McGarry, D.J.; Chakravarty, P.; Wolf, C.R.; Henderson, C.J. Altered Protein S-Glutathionylation Identifies
a Potential Mechanism of Resistance to Acetaminophen-Induced Hepatotoxicity. J. Pharmacol. Exp. Ther.
2015, 355, 137–144. [CrossRef] [PubMed]
Antioxidants 2019, 8, 315 20 of 25
68. Navarro-Yepes, J.; Burns, M.; Anandhan, A.; Khalimonchuk, O.; Del Razo, L.M.; Quintanilla-Vega, B.;
Pappa, A.; Panayiotidis, M.I.; Franco, R. Oxidative Stress, Redox Signaling, and Autophagy: Cell Death
Versus Survival. Antioxid. Redox Signal. 2014, 21, 66–85. [CrossRef] [PubMed]
69. Okamoto, T.; Akaike, T.; Sawa, T.; Miyamoto, Y.; Van Der Vliet, A.; Maeda, H. Activation of Matrix
Metalloproteinases by Peroxynitrite-induced ProteinS-Glutathiolation via DisulfideS-Oxide Formation.
J. Boil. Chem. 2001, 276, 29596–29602. [CrossRef]
70. Mukherjee, T.K.; Mishra, A.K.; Mukhopadhyay, S.; Hoidal, J.R. High Concentration of Antioxidants
N-Acetylcysteine and Mitoquinone-Q Induces Intercellular Adhesion Molecule 1 and Oxidative Stress by
Increasing Intracellular Glutathione. J. Immunol. 2014, 178, 1835–1844. [CrossRef]
71. Stojkov, D.; Amini, P.; Oberson, K.; Sokollik, C.; Duppenthaler, A.; Simon, H.-U.; Yousefi, S. ROS and
glutathionylation balance cytoskeletal dynamics in neutrophil extracellular trap formation. J. Cell Boil. 2017,
216, 4073–4090. [CrossRef]
72. Fiaschi, T.; Cozzi, G.; Raugei, G.; Formigli, L.; Ramponi, G.; Chiarugi, P. Redox regulation of β-actin during
integrin-mediated cell adhesion. J. Biol. Chem. 2006, 281, 22983–22991. [CrossRef] [PubMed]
73. Wang, J.; Boja, E.S.; Tan, W.; Tekle, E.; English, S.; Mieyal, J.J.; Chock, P.B.; Fales, H.M. Reversible
Glutathionylation Regulates Actin Polymerization in A431 Cells. J. Boil. Chem. 2001, 276, 47763–47766.
[CrossRef] [PubMed]
74. Chen, W.; Seefeldt, T.; Young, A.; Zhang, X.; Zhao, Y.; Ruffolo, J.; Kaushik, R.S.; Guan, X. Microtubule
S-glutathionylation as a potential approach for antimitotic agents. BMC Cancer 2012, 12, 245. [CrossRef]
[PubMed]
75. Landino, L.M.; Moynihan, K.L.; Todd, J.V.; Kennett, K.L. Modulation of the redox state of tubulin by the
glutathione/glutaredoxin reductase system. Biochem. Biophys. Res. Commun. 2004, 314, 555–560. [CrossRef]
[PubMed]
76. Yan, M.S.; Marsden, P.A. Epigenetics in the Vascular Endothelium: Looking from a different perspective in
the epigenomics era. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 2297–2306. [CrossRef] [PubMed]
77. Berezin, A.E. Epigenetic Mechanisms of Endothelial Progenitor Cell Dysfunction. J. Clin. Epigenet. 2016, 2.
[CrossRef]
78. Fraineau, S.; Brand, M.; Palii, C.G.; Allan, D.S. Epigenetic regulation of endothelial-cell-mediated vascular
repair. FEBS J. 2015, 282, 1605–1629. [CrossRef] [PubMed]
79. Dutta, D.; Ray, S.; Home, P.; Saha, B.; Wang, S.; Sheibani, N.; Tawfik, O.; Cheng, N.; Paul, S. Regulation of
Angiogenesis by Histone Chaperone HIRA-mediated Incorporation of Lysine 56-acetylated Histone H3.3 at
Chromatin Domains of Endothelial Genes. J. Boil. Chem. 2010, 285, 41567–41577. [CrossRef]
80. Fish, J.E.; Matouk, C.C.; Rachlis, A.; Lin, S.; Tai, S.C.; D’Abreo, C.; Marsden, P.A. The Expression of Endothelial
Nitric-oxide Synthase Is Controlled by a Cell-specific Histone Code. J. Boil. Chem. 2005, 280, 24824–24838.
[CrossRef]
81. Urbich, C.; Dimmeler, S.; Zeiher, A.M.; Rossig, L.; Diehl, F. The histone methyltransferase MLL is an upstream
regulator of endothelial-cell sprout formation. Blood 2006, 109, 1472–1478.
82. Kreuz, S.; Fischle, W. Oxidative stress signaling to chromatin in health and disease. Epigenomics 2016,
8, 843–862. [CrossRef] [PubMed]
83. Downs, J.A.; Nussenzweig, M.C.; Nussenzweig, A. Chromatin dynamics and the preservation of genetic
information. Nature 2007, 447, 951–958. [CrossRef] [PubMed]
84. Panyim, S.; Sommer, K.R.; Chalkley, R. Oxidation of the cysteine-containing histone F3. Detection of
an evolutionary mutation in a conservative histone. Biochemistry 1971, 10, 3911–3917. [CrossRef] [PubMed]
85. Blackshire, B. The effects of histone glutathionylation on chromatin structure. FASEB J. 2014, 28, 942–945.
86. Colussi, C.; Mozzetta, C.; Gurtner, A.; Illi, B.; Rosati, J.D.; Straino, S.; Ragone, G.; Pescatori, M.; Zaccagnini, G.;
Antonini, A.; et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common
target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. USA 2008, 105, 19183–19187.
[CrossRef] [PubMed]
87. Yu, J.; Wu, Y.; Yang, P. High glucose-induced oxidative stress represses sirtuin deacetylase expression and
increases histone acetylation leading to neural tube defects. J. Neurochem. 2016, 137, 371–383. [CrossRef]
[PubMed]
88. Santos, L.; Escande, C.; Denicola, A. Potential modulation of sirtuins by oxidative stress.Oxid. Med. Cell. Longev.
2016, 2016, 1–12. [CrossRef] [PubMed]
Antioxidants 2019, 8, 315 21 of 25
89. Hashimoto-Komatsu, A.; Hirase, T.; Asaka, M.; Node, K. Angiotensin II induces microtubule reorganization
mediated by a deacetylase SIRT2 in endothelial cells. Hypertens. Res. 2011, 34, 949–956. [CrossRef] [PubMed]
90. Maizel, J.; Xavier, S.; Chen, J.; Lin, C.H.S.; Vasko, R.; Goligorsky, M.S. Sirtuin 1 ablation in endothelial cells
is associated with impaired angiogenesis and diastolic dysfunction. Am. J. Physiol. Circ. Physiol. 2014,
307, H1691–H1704. [CrossRef] [PubMed]
91. Ghisays, F.; Brace, C.S.; Yackly, S.M.; Kwon, H.J.; Mills, K.F.; Kashentseva, E.; Dimitriev, I.P.; Curiel, D.T.;
Imai, S.-I.; Ellenberger, T. The N-terminal Domain of SIRT1 Is a Positive Regulator of Endogenous
SIRT1-dependent Deacetylation and Transcriptional Outputs. Cell Rep. 2015, 10, 1665–1673. [CrossRef]
92. Yeung, F.; E Hoberg, J.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; A Frye, R.; Mayo, M.W. Modulation of
NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23, 2369–2380.
[CrossRef] [PubMed]
93. Xia, N.; Strand, S.; Schlufter, F.; Siuda, D.; Reifenberg, G.; Kleinert, H.; Förstermann, U.; Li, H. Role of SIRT1
and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 2013, 32, 29–35. [CrossRef]
[PubMed]
94. Mattagajasingh, I.; Kim, C.-S.; Naqvi, A.; Yamamori, T.; Hoffman, T.A.; Jung, S.-B.; DeRicco, J.; Kasuno, K.;
Irani, K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide
synthase. Proc. Natl. Acad. Sci. USA 2007, 104, 14855–14860. [CrossRef] [PubMed]
95. Kempe, S.; Kestler, H.; Lasar, A.; Wirth, T. NF-κB controls the global pro-inflammatory response in endothelial
cells: Evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res. 2005, 33, 5308–5319.
[CrossRef] [PubMed]
96. Shi, Y.-N.; Zhu, N.; Liu, C.; Wu, H.-T.; Gui, Y.; Liao, D.-F.; Qin, L. Wnt5a and its signaling pathway in
angiogenesis. Clin. Chim. Acta 2017, 471, 263–269. [CrossRef] [PubMed]
97. Qanungo, S.; Starke, D.W.; Pai, H.V.; Mieyal, J.J.; Nieminen, A.-L. Glutathione Supplementation Potentiates
Hypoxic Apoptosis by S-Glutathionylation of p65-NFκB. J. Boil. Chem. 2007, 282, 18427–18436. [CrossRef]
[PubMed]
98. Folkman, J. Angiogenesis and c-Jun. J. Natl. Cancer Inst. 2004, 96, 644. [CrossRef] [PubMed]
99. Ma, J.; Zhang, L.; Han, W.; Shen, T.; Ma, C.; Liu, Y.; Nie, X.; Liu, M.; Ran, Y.; Zhu, D. Activation of JNK/c-Jun
is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial
cells. J. Lipid Res. 2012, 53, 1093–1105. [CrossRef] [PubMed]
100. Vleugel, M.M.; Greijer, A.E.; Bos, R.; Van Der Wall, E.; Van Diest, P.J. c-Jun activation is associated with
proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 2006, 37, 668–674. [CrossRef] [PubMed]
101. Yamakuchi, M.; Panta, S.; Hashiguchi, T. p53 and Vascular Dysfunction: MicroRNA in Endothelial
Cells, Vasculitis in Practice—An Update on Special Situations—Clinical and Therapeutic Considerations.
IntechOpen 2018. [CrossRef]
102. Chen, B.; Lu, Y.; Chen, Y.; Cheng, J. The role of Nrf2 in oxidative stress-induced endothelial injuries.
J. Endocrinol. 2015, 225, R83–R99. [CrossRef] [PubMed]
103. Florczyk, U.; Jazwa, A.; Maleszewska, M.; Mendel, M.; Szade, K.; Kozakowska, M.; Grochot-Przeczek, A.;
Viscardi, M.; Czauderna, S.; Bukowska-Strakova, K.; et al. Nrf2 Regulates Angiogenesis: Effect on Endothelial
Cells, Bone Marrow-Derived Proangiogenic Cells and Hind Limb Ischemia. Antioxid. Redox Signal. 2013,
20, 1693–1708. [CrossRef] [PubMed]
104. Manalo, D.J.; Rowan, A.; Lavoie, T.; Natarajan, L.; Kelly, B.D.; Shui, Q.Y.; Garcia, J.G.N.; Semenza, G.L.
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105, 564–565.
[CrossRef] [PubMed]
105. Iyer, N.V.; Kotch, L.E.; Agani, F.; Leung, S.W.; Laughner, E.; Wenger, R.H.; Gassmann, M.; Gearhart, J.D.;
Lawler, A.M.; Yu, A.Y.; et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible
factor 1α. Genome Res. 1998, 12, 149–162.
106. Rawlings, J.S. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117, 1281–1283. [CrossRef] [PubMed]
107. Bartoli, M.; Gu, X.; Tsai, N.T.; Venema, R.C.; Brooks, S.E.; Marrero, M.B.; Caldwell, R.B. Vascular Endothelial
Growth Factor Activates STAT Proteins in Aortic Endothelial Cells. J. Boil. Chem. 2000, 275, 33189–33192.
[CrossRef] [PubMed]
108. Chen, S.-H.; Murphy, D.A.; Lassoued, W.; Thurston, G.; Feldman, M.D.; Lee, W.M. Activated STAT3 is
a mediator and biomarker of VEGF endothelial activation. Cancer Boil. Ther. 2008, 7, 1994–2003. [CrossRef]
[PubMed]
Antioxidants 2019, 8, 315 22 of 25
109. Fernández-Laso, V.; Sastre, C.; Méndez-Barbero, N.; Egido, J.; Martín-Ventura, J.L.; Gómez-Guerrero, C.;
Blanco-Colio, L.M. TWEAK blockade decreases atherosclerotic lesion size and progression through
suppression of STAT1 signaling in diabetic mice. Sci. Rep. 2017, 7, 46679. [CrossRef] [PubMed]
110. Wang, R.; Zhang, Y.; Xu, L.; Lin, Y.; Yang, X.; Bai, L.; Chen, Y.; Zhao, S.; Fan, J.; Cheng, X.; et al. Protein
Inhibitor of Activated STAT3 Suppresses Oxidized LDL-induced Cell Responses during Atherosclerosis in
Apolipoprotein E-deficient Mice. Sci. Rep. 2016, 6, 36790. [CrossRef]
111. Xue, C.; Xie, J.; Zhao, D.; Lin, S.; Zhou, T.; Shi, S.; Shao, X.; Lin, Y.; Zhu, B.; Cai, X. The JAK/STAT3 signalling
pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model.
Cell Prolif. 2017, 50, 1–10. [CrossRef]
112. Battle, T.E.; Lynch, R.A.; Frank, D.A. Signal Transducer and Activator of Transcription 1 Activation in
Endothelial Cells Is a Negative Regulator of Angiogenesis. Cancer Res. 2006, 66, 3649–3657. [CrossRef]
[PubMed]
113. Rhee, S.G.; Bae, Y.S.; Lee, S.-R.; Kwon, J. Hydrogen Peroxide: A Key Messenger That Modulates Protein
Phosphorylation Through Cysteine Oxidation. Sci. Signal. 2000, 2000, pe1. [CrossRef] [PubMed]
114. Klomsiri, C.; Karplus, P.A.; Poole, L.B. Cysteine-Based Redox Switches in Enzymes. Antioxid. Redox Signal.
2010, 14, 1065–1077. [CrossRef] [PubMed]
115. Chiarugi, P. The Redox Regulation of LMW-PTP During Cell Proliferation or Growth Inhibition. IUBMB Life
2001, 52, 55–59. [CrossRef] [PubMed]
116. Giannoni, E.; Raugei, G.; Chiarugi, P.; Ramponi, G. A novel redox-based switch: LMW-PTP oxidation
enhances Grb2 binding and leads to ERK activation. Biochem. Biophys. Res. Commun. 2006, 348, 367–373.
[CrossRef] [PubMed]
117. Xing, K.; Raza, A.; Löfgren, S.; Fernando, M.R.; Ho, Y.S.; Lou, M.F. LMW-PTP and Its Possible Physiological
Functions of redox signaling in the eye lens. Biochim. Biophys. Acta. 2007, 1774, 545–555. [CrossRef] [PubMed]
118. Nakamura, Y.; Patrushev, N.; Inomata, H.; Mehta, D.; Urao, N.; Kim, H.W.; Razvi, M.; Kini, V.; Mahadev, K.;
Goldstein, B.J.; et al. Role of Protein Tyrosine Phosphatase 1B in VEGF Signaling and Cell-Cell Adhesions in
Endothelial Cells. Circ. Res. 2008, 102, 1182–1191. [CrossRef] [PubMed]
119. Besnier, M.; Galaup, A.; Nicol, L.; Henry, J.-P.; Coquerel, D.; Gueret, A.; Mulder, P.; Brakenhielm, E.;
Thuillez, C.; Germain, S.; et al. Enhanced angiogenesis and increased cardiac perfusion after myocardial
infarction in protein tyrosine phosphatase 1B-deficient mice. FASEB J. 2014, 28, 3351–3361. [CrossRef]
[PubMed]
120. Huang, L.; Sankar, S.; Lin, C.; Kontos, C.D.; Schroff, A.D.; Cha, E.H.; Feng, S.-M.; Li, S.-F.; Yu, Z.;
Van Etten, R.L.; et al. HCPTPA, a Protein Tyrosine Phosphatase That Regulates Vascular Endothelial Growth
Factor Receptor-mediated Signal Transduction and Biological Activity. J. Boil. Chem. 1999, 274, 38183–38188.
[CrossRef] [PubMed]
121. Kilzer, P.; Chang, K.; Marvel, J.; Rowold, E.; Jaudes, P.; Ullensvang, S.; Kilo, C.; Williamson, J.R. Albumin
Permeation of New Vessels Is Increased in Diabetic Rats. Diabetes 1985, 34, 333–336. [CrossRef]
122. Williamson, J.R.; Chang, K.; Tilton, R.G.; Prater, C.; Jeffrey, J.R.; Weigel, C.; Sherman, W.R.; Eades, D.M.;
Kilo, C. Increased Vascular Permeability in Spontaneously Diabetic BB/W Rats and in Rats with Mild Versus
Severe Streptozocin-Induced Diabetes - Prevention by Aldose Reductase Inhibitors and Castration. Diabetes
1987, 36, 813–821. [CrossRef] [PubMed]
123. Usatyuk, P.V.; Vepa, S.; Watkins, T.; He, D.; Parinandi, N.L.; Natarajan, V. Redox Regulation of Reactive
Oxygen Species-Induced p38 MAP Kinase Activation and Barrier Dysfunction in Lung Microvascular
Endothelial Cells. Antioxid. Redox Signal. 2003, 5, 723–730. [CrossRef] [PubMed]
124. Vandenbroucke, E.; Mehta, D.; Minshall, R.; Malik, A.B. Regulation of Endothelial Junctional Permeability.
Ann. N. Y. Acad. Sci. 2008, 1123, 134–145. [CrossRef] [PubMed]
125. Ridley, A.J. Rho GTPase signalling in cell migration. Curr. Opin. Cell Boil. 2015, 36, 103–112. [CrossRef]
[PubMed]
126. Selvakumar, B.; Hess, D.T.; Goldschmidt-clermont, P.J.; Stamler, J.S. Co-regulation of constitutive nitric oxide
synthase and NADPH oxidase by the small GTPase Rac. Measurement 2009, 582, 2195–2202. [CrossRef]
[PubMed]
127. Haeussler, D.J.; Pimentel, D.R.; Hou, X.; Burgoyne, J.R.; Cohen, R.A.; Bachschmid, M.M. Endomembrane
H-Ras Controls Vascular Endothelial Growth Cell Migration. J. Biol. Chem. 2013, 288, 15380–15389. [CrossRef]
[PubMed]
Antioxidants 2019, 8, 315 23 of 25
128. Küppers, V.; Vockel, M.; Nottebaum, A.F.; Vestweber, D. Phosphatases and kinases as regulators of the
endothelial barrier function. Cell Tissue Res. 2014, 355, 577–586. [CrossRef] [PubMed]
129. Bogatcheva, N.V.; Dudek, S.M.; Garcia, J.G.N.; Verin, A.D. Mitogen-Activated Protein Kinases in Endothelial
Pathophysiology. J. Investig. Med. 2003, 51, 341–352. [CrossRef] [PubMed]
130. Ray, R.; Shah, A.M. NADPH oxidase and endothelial cell function. Clin. Sci. 2005, 109, 217–226. [CrossRef]
[PubMed]
131. Haddad, P.; Dussault, S.; Groleau, J.; Turgeon, J.; Michaud, S.-E.; Ménard, C.; Perez, G.; Maingrette, F.;
Rivard, A.; Ménard, C. Nox2-Containing NADPH Oxidase Deficiency Confers Protection from Hindlimb
Ischemia in Conditions of Increased Oxidative Stress. Arter. Thromb. Vasc. Boil. 2009, 29, 1522–1528. [CrossRef]
[PubMed]
132. Murdoch, C.E.; Cave, A.C.; Zhang, M.; Shah, A.M. NADPH oxidase-dependent redox signalling in cardiac
hypertrophy, remodelling and failure. Cardiovasc. Res. 2006, 71, 208–215. [CrossRef] [PubMed]
133. Sirker, A.; Murdoch, C.E.; Protti, A.; Sawyer, G.J.; Santos, C.X.; Martin, D.; Zhang, X.; Brewer, A.C.; Zhang, M.;
Shah, A.M. Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction. J. Mol.
Cell. Cardiol. 2016, 98, 11–17. [CrossRef] [PubMed]
134. Murdoch, C.E.; Chaubey, S.; Zeng, L.; Yu, B.; Ivetic, A.; Walker, S.J.; Vanhoutte, D.; Heymans, S.; Grieve, D.J.;
Cave, A.C.; et al. Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic
Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition. J. Am. Coll. Cardiol.
2014, 63, 2734–2741. [CrossRef] [PubMed]
135. Guzik, T.J.; Sadowski, J.; Guzik, B.; Jopek, A.; Kapelak, B.; Przybyłowski, P.; Wierzbicki, K.; Korbut, R.;
Harrison, D.G.; Channon, K.M. Coronary Artery Superoxide Production and Nox Isoform Expression in
Human Coronary Artery Disease. Arter. Thromb. Vasc. Boil. 2006, 26, 333–339. [CrossRef] [PubMed]
136. Mythreye, K.; Goldschmidt-Clermont, P.J.; Satterwhite, L.L.; Moldovan, L. Reactive oxygen species in
vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc. Res. 2006, 71, 236–246.
137. Ushio-Fukai, M. Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovasc. Res. 2006, 71, 226–235.
[CrossRef]
138. Li, J.-M.; Mullen, A.M.; Yun, S.; Wientjes, F.; Brouns, G.Y.; Thrasher, A.J.; Shah, A.M. Essential Role of the
NADPH Oxidase Subunit p47 phox in Endothelial Cell Superoxide Production in Response to Phorbol Ester
and Tumor Necrosis Factor-α. Circ. Res. 2002, 90, 143–150. [CrossRef] [PubMed]
139. Bernard, L.; Clempus, R. Vascular NAD (P) H oxidases: Specific features, expression, and regulation. Am. J.
Physiol. 2003, 285, R277–R297.
140. Tang, X.; Luo, Y.-X.; Chen, H.-Z.; Liu, D.-P. Mitochondria, endothelial cell function, and vascular diseases.
Front. Physiol. 2014, 5, 1–17. [CrossRef]
141. Tousoulis, D.; Kampoli, A.-M.; Tentolouris Nikolaos Papageorgiou, C.; Stefanadis, C. The Role of Nitric
Oxide on Endothelial Function. Curr. Vasc. Pharmacol. 2011, 10, 4–18. [CrossRef]
142. Crabtree, M.J.; Brixey, R.; Batchelor, H.; Hale, A.B.; Channon, K.M. Integrated Redox Sensor and Effector
Functions for Endothelial Nitric-oxide Synthase (eNOS) Uncoupling. J. Biol. Chem. 2013, 288, 561–569.
[CrossRef] [PubMed]
143. Tran, Q.-K.; Ohashi, K.; Watanabe, H. Calcium signalling in endothelial cells. Cardiovasc. Res. 2000, 48, 13–22.
[CrossRef]
144. Raturi, A.; Ortiz-Sandoval, C.; Simmen, T. Redox dependence of endoplasmic reticulum (ER) Ca2+ signaling.
Histol. Histopathol. 2014, 29, 543–552. [PubMed]
145. Tong, X.Y.; Evangelista, A.; Cohen, R.A. Targeting the Redox Regulation of SERCA in Vascular Physiology
and Disease. Curr. Opin. Pharmacol. 2010, 10, 133–138. [CrossRef] [PubMed]
146. Adachi, T.; Weisbrod, R.M.; Pimentel, D.R.; Ying, J.; Sharov, V.S.; Schöneich, C.; Cohen, R.A. S-Glutathiolation
by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat. Med. 2004, 10, 1200–1207.
[CrossRef] [PubMed]
147. Evangelista, A.M.; Thompson, M.D.; Weisbrod, R.M.; Pimental, D.R.; Tong, X.Y.; Bolotina, V.M.; Cohen, R.A.
Redox Regulation of SERCA2 Is Required for Vascular Endothelial Growth Factor-Induced Signaling and
Endothelial Cell Migration. Antioxid. Redox Signal. 2012, 17, 1099–1108. [CrossRef] [PubMed]
148. Yazbeck, P.; Tauseef, M.; Kruse, K.; Amin, M.R.; Sheikh, R.; Feske, S.; Komarova, K.; Mehta, D. STIM1
Phosphorylation at Y361 Recruits Orai1 to STIM1 Puncta and Induces Ca2+ Entry. Sci. Rep. 2017, 7, 1–11.
[CrossRef]
Antioxidants 2019, 8, 315 24 of 25
149. Watson, E.C.; Grant, Z.L.; Coultas, L. Endothelial cell apoptosis in angiogenesis and vessel regression.
Cell. Mol. Life Sci. 2017, 74, 4387–4403. [CrossRef]
150. Paone, S.; Baxter, A.A.; Hulett, M.D.; Poon, I.K.H. Endothelial cell apoptosis and the role of endothelial
cell-derived extracellular vesicles in the progression of atherosclerosis. Cell. Mol. Life Sci. 2018, 76, 1093–1106.
[CrossRef]
151. Warren, M.C.; A Bump, E.; Medeiros, D.; Braunhut, S.J. Oxidative stress–induced apoptosis of endothelial
cells. Free Radic. Boil. Med. 2000, 29, 537–547. [CrossRef]
152. Kobayashi, N.; Delano, F.A.; Schmid-Schoönbein, G.W. Oxidative Stress Promotes Endothelial Cell Apoptosis
and Loss of Microvessels in the Spontaneously Hypertensive Rats.Arter. Thromb. Vasc. Boil. 2005, 25, 2114–2121.
[CrossRef] [PubMed]
153. Thorburn, A. Death receptor-induced cell killing. Cell. Signal. 2004, 16, 139–144. [CrossRef] [PubMed]
154. Sata, M.; Suhara, T.; Walsh, K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas
and Fas ligand and in sensitivity to Fas ligand-induced cell death: Implications for vascular disease and
therapy. Arter. Thromb. Vasc. Boil. 2000, 20, 309–316. [CrossRef]
155. Kamei, R.; Tanaka, H.Y.; Kawano, T.; Morii, C.; Tanaka, S.; Nishihara, H.; Iwata, C.; Kano, M.R. Regulation
of endothelial Fas expression as a mechanism of promotion of vascular integrity by mural cells in tumors.
Cancer Sci. 2017, 108, 1080–1088. [CrossRef] [PubMed]
156. Scheer, J.M.; Romanowski, M.J.; Wells, J.A. A common allosteric site and mechanism in caspases. Proc. Natl.
Acad. Sci. USA 2006, 103, 7595–7600. [CrossRef] [PubMed]
157. Filomeni, G.; De Zio, D.; Cecconi, F. Oxidative stress and autophagy: The clash between damage and
metabolic needs. Cell Death Differ. 2015, 22, 377–388. [CrossRef] [PubMed]
158. Schaaf, M.B.; Houbaert, D.; Meçe, O.; Agostinis, P. Autophagy in endothelial cells and tumor angiogenesis.
Cell Death Differ. 2019, 26, 665–679. [CrossRef] [PubMed]
159. Boteon, Y.L.; Laing, R.; Mergental, H.; Reynolds, G.M.; Mirza, D.F.; Afford, S.C.; Bhogal, R.H. Mechanisms of
autophagy activation in endothelial cell and their targeting during normothermic machine liver perfusion.
World J. Gastroenterol. 2017, 23, 8443–8451. [CrossRef] [PubMed]
160. Jiang, F. Autophagy in vascular endothelial cells. Clin. Exp. Pharmacol. Physiol. 2016, 43, 1021–1028.
[CrossRef] [PubMed]
161. Yi, F.; Hao, Y.; Chong, X.; Zhong, W. Overexpression of microRNA-506-3p aggravates the injury of vascular
endothelial cells in patients with hypertension by downregulating Beclin1 expression. Exp. Ther. Med. 2018,
15, 2844–2850. [CrossRef]
162. Geng, Z.; Xu, F.; Zhang, Y. MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in
atherosclerosis. Am. J. Transl. Res. 2016, 8, 1886–1894. [PubMed]
163. Rundhaug, J.E. Matrix metalloproteinases and angiogenesis Angiogenesis Review Series. J. Cell. Mol. Med.
2005, 9, 267–285. [CrossRef] [PubMed]
164. Florence, J.M.; Krupa, A.; Booshehri, L.M.; Allen, T.C.; Kurdowska, A.K. Metalloproteinase-9 contributes to
endothelial dysfunction in atherosclerosis via protease activated receptor-1. PLoS ONE 2017, 12, e0171427.
[CrossRef] [PubMed]
165. Papazafiropoulou, A.; Tentolouris, N. Matrix metalloproteinases and cardiovascular diseases. Hippokratia
2009, 13, 76–82. [PubMed]
166. Nelson, K.K.; Subbaram, S.; Connor, K.M.; Dasgupta, J.; Ha, X.-F.; Meng, T.-C.; Tonks, N.K.; Melendez, J.A.
Redox-dependent Matrix Metalloproteinase-1 Expression Is Regulated by JNK through Ets and AP-1
Promoter Motifs. J. Boil. Chem. 2006, 281, 14100–14110. [CrossRef] [PubMed]
167. Kar, S.; Subbaram, S.; Carrico, P.M.; Melendez, J.A. Redox-control of Matrix Metalloproteinase-1: A critical
link between free radicals, matrix remodeling and degenerative disease. Respir. Physiol. Neurobiol. 2010,
174, 299–306. [CrossRef] [PubMed]
168. Rajagopalan, S.; Meng, X.P.; Ramasamy, S.; Harrison, D.G.; Galis, Z.S. Reactive oxygen species produced
by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro.
Implications for atherosclerotic plaque stability. J. Clin. Investig. 1996, 98, 2572–2579. [CrossRef] [PubMed]
169. Stupack, D.G.; Cheresh, D.A. Integrins and Angiogenesis. Curr. Top. Dev. Biol. 2004, 64, 207–238. [PubMed]
170. Eble, J.A.; de Rezende, F.F. Redox-Relevant Aspects of the Extracellular Matrix and Its Cellular Contacts via
Integrins. Antioxid. Redox Signal. 2013, 20, 1977–1993. [CrossRef]
Antioxidants 2019, 8, 315 25 of 25
171. Liu, S.-Y.; Tsai, M.-Y.; Chuang, K.-P.; Huang, Y.-F.; Shieh, C.-C. Ligand binding of leukocyte integrin very late
antigen-4 involves exposure of sulfhydryl groups and is subject to redox modulation. Eur. J. Immunol. 2008,
38, 410–423. [CrossRef]
172. You, Y.; Chen, J.; Zhu, F.; Xu, Q.; Han, L.; Gao, X.; Zhang, X.; Luo, H.R.; Miao, J.; Sun, X.; et al. Glutaredoxin 1
up-regulates deglutathionylation of α4 integrin and thereby restricts neutrophil mobilization from bone
marrow. J. Biol. Chem. 2019, 294, 2616–2627. [CrossRef] [PubMed]
173. Deem, T.L.; Cook-Mills, J.M. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell
matrix metalloproteinases: Role of reactive oxygen species. Blood 2004, 104, 2385–2393. [CrossRef] [PubMed]
174. Kong, D.-H.; Kim, Y.K.; Kim, M.R.; Jang, J.H.; Lee, S. Emerging Roles of Vascular Cell Adhesion Molecule-1
(VCAM-1) in Immunological Disorders and Cancer. Int. J. Mol. Sci. 2018, 19, 1057. [CrossRef] [PubMed]
175. Fearnley, G.W.; Odell, A.F.; Latham, A.M.; Mughal, N.A.; Bruns, A.F.; Burgoyne, N.J.; Homer-Vanniasinkam, S.;
Zachary, I.C.; Hollstein, M.C.; Wheatcroft, S.B.; et al. VEGF-A isoforms differentially regulate ATF-2–dependent
VCAM-1 gene expression and endothelial–leukocyte interactions.Mol. Boil. Cell2014, 25, 2509–2521. [CrossRef]
[PubMed]
176. Wilson, C.; Gonzalez-Billault, C. Regulation of cytoskeletal dynamics by redox signaling and oxidative stress:
Implications for neuronal development and trafficking. Front. Cell. Neurosci. 2015, 9, 1–10. [CrossRef]
[PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
